Panelists introduce key CDK4/6 inhibitor data from ESMO 2025, setting the stage for insightful discussions on pivotal clinical trials and questions.
Back
ESMO 2025 Highlights in Breast Cancer Treatment with CDK4/6 Inhibitors
The CDK4/6 Breast Cancer ESMO Insights Series brings together leading oncology pharmacy experts to break down the most impactful data shaping the future of HR-positive breast cancer care. Across this multi-part program, our panel examines pivotal updates from the monarchE, NATALEE, and VIKTORIA-1 trials—translating complex clinical findings into practical, actionable insights for clinicians. From adjuvant therapy outcomes to advances in the post–CDK4/6 inhibitor metastatic setting, this series is designed to help pharmacists and care teams understand how emerging evidence will influence treatment decisions and optimize care for patients across the disease continuum.
ESMO 2025 Highlights in Breast Cancer Treatment with CDK4/6 Inhibitors
Episodes
All
All
New findings reveal a modest overall survival benefit of abemaciclib in early breast cancer, highlighting the importance of ongoing patient education and treatment strategies.
In this segment, the panel unpacks the 5-year results from the NATALEE trial, which evaluated ribociclib plus a nonsteroidal aromatase inhibitor in early HR+/HER2– breast cancer.
In this segment, the experts dive into the monarchE subanalysis evaluating how Ki-67 levels before and after neoadjuvant chemotherapy inform prognosis and treatment planning for high-risk HR+, HER2– early breast cancer.
In this segment, the experts turn their attention to metastatic HR+/HER2– breast cancer, examining the first results from the VIKTORIA-1 trial evaluating gedatolisib in combination with fulvestrant with or without palbociclib.
In the final segment, the panelists bring together the major insights from across the series, highlighting the most clinically meaningful data from monarchE, NATALEE, and VIKTORIA-1 and what these findings mean for the evolving role of CDK4/6 inhibitors in both early-stage and metastatic HR+ breast cancer.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists Weigh Health, Not Just Weight, in Obesity Care
2
Building a CDTM Program Means Starting Small
3
Extended-Interval Tarlatamab Dosing Offers Pharmacists More Flexible Administration Windows in SCLC
4
Pharmacists as the Glue in Cardio-Kidney-Metabolic Care
5